Publications

Publications

  1. Cox MS, Dill-McFarland KA, Simmons JD, Benchek P, Mayanja-Kizza H, Boom WH, Stein CM, Hawn TR. Multi-omic latent variable data integration reveals multicellular structure pathways associated with resistance to tuberculin skin test (TST)/interferon gamma release assay (IGRA) conversion in Uganda. BMC Genomics. 2025 Mar 18;26(1):265. doi: 10.1186/s12864-025-11407-1. PMID: 40102730.
  2. Dirajlal-Fargo S, Nikahd M, Ailstock K, Manubolu M, Musiime V, Kityo C, McComsey GA, Funderburg NT. Changes in the Lipidome Are Associated With Immune Activation and Subclinical Vascular Disease in Youth With Human Immunodeficiency Virus in Uganda. J Infect Dis. 2025 Feb 20;231(2):403-413. doi: 10.1093/infdis/jiae461. PMID: 39331511; PMCID: PMC11841650.
  3. Gutierrez J, Malone LL, Mohammadi M, Mukisa J, Atuhairwe M, Mwesigwa SPG, Athieno S, Buwule S, Ameda F, Kiyingi S, Mupere E, Stein CM, Lancioni CL. Immune-sensitization to Mycobacterium tuberculosis Among Young Children With and Without Tuberculosis. medRxiv [Preprint]. 2025 Jan 17:2025.01.16.25320625. doi: 10.1101/2025.01.16.25320625. PMID: 39867405; PMCID: PMC11759604.
  4. Jemutai J, Njuguna RG, Laurence YV, Murunga S, Ogwang C, Mwaringa S, Mwalekwa L, Timbwa M, Paasi G, Olupot-Olupot P, Juma M, Thitiri J, Ngao N, Singa B, Mukisa J, Mupere E, Lancioni C, Sukhtankar P, Tickell KD, Fakhar Uddin M, Molyneux S, Walson JL, Vassall A, Berkley J. Catastrophic expenditure associated with childhood hospitalisation for acute illness in Kenya and Uganda: a cross-sectional study. BMJ Public Health. 2025 Jan 16;3(1):e001173. doi: 10.1136/bmjph-2024-001173. PMID: 40017943; PMCID: PMC11812878.
  5. Nankya I, Natukunda E, Rutebarika D, Matama C, Basiimwa R, Arikod P, Muwabe F, Otike C, Kityo C. High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV. AIDS Res Ther. 2025 Mar 11;22(1):34. doi: 10.1186/s12981-025-00701-3. PMID: 40069769; PMCID: PMC11899026.
  6. Nanteza A, Gumikiriza-Onoria J, Santoro AF, Karungi C, Ferraris CM, Tsapalas D, Kirsch C, Nguyen M, Asiedu N, Tan M, Liu J, Dolezal C, Musiime V, Dirajlal-Fargo S, Robbins RN. Reported Suicide Attempts among Adolescents in Uganda: Differences by HIV Status. AIDS Behav. 2025 Mar;29(3):1004-1010. doi: 10.1007/s10461-024-04581-y. Epub 2024 Dec 30. PMID: 39739277.
  7. White E, Kityo C, Spyer MJ, Mujuru HA, Nankya I, Kekitiinwa AR, Lugemwa A, Kaudha E, Liberty A, Cassim H, Archary M, Cotton MF, Ahimbisibwe GM, Cressey TR, Ngampiyaskul C, Srirompotong U, Behuhuma O, Saidi Y, Bamford A, Kobbe R, Nastouli E, Rojo P, Giaquinto C, Gibb DM, Ford D, Turkova A; ODYSSEY trial team. Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar;12(3):e201-e213. doi: 10.1016/S2352-3018(24)00155-3. Epub 2025 Feb 17. PMID: 39978387.
  1. Baluku JB, Namiiro S, Namanda B, Nabwana M, Andia-Biraro I, Worodria W, Salata R, Mfinanga S, Gerson S, Kirenga B. Neutrophil-Lymphocyte and platelet-lymphocyte ratios in distinguishing lung cancer in people with HIV. Dis Markers. 2024 Jan 23;2024:8822024. doi: 10.1155/2024/8822024. PMID: 38292339; PMCID: PMC10827363.
  2. Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM; AIDS Clinical Trial Group; Tuberculosis Trials Consortium. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024 Oct 30;15(1):9400. doi: 10.1038/s41467-024-53273-7. PMID: 39477924; PMCID: PMC11526018.
  3. Childhood Acute Illness and Nutrition (CHAIN) Network. Hospital readmission following acute illness among children 2-23 months old in sub-Saharan Africa and South Asia: a secondary analysis of CHAIN cohort. EClinicalMedicine. 2024 Jun 7;73:102676. doi: 10.1016/j.eclinm.2024.102676. PMID: 38933099; PMCID: PMC11200276.
  4. Cross DL, Layton ED, Yu KK, Smith MT, Aguilar MS, Li S, Wilcox EC, Chapuis AG, Mayanja-Kizza H, Stein CM, Boom WH, Hawn TR, Bradley P, Newell EW, Seshadri C. MR1-restricted T cell clonotypes are associated with "resistance" to Mycobacterium tuberculosis infection. JCI Insight. 2024 May 8;9(9):e166505. doi: 10.1172/jci.insight.166505. PMID: 38716731.
  5. Davies LRL, Wang C, Steigler P, Bowman KA, Fischinger S, Hatherill M, Fisher M, Mbandi SK, Rodo M, Ottenhoff THM, Dockrell HM, Sutherland JS, Mayanja-Kizza H, Boom WH, Walzl G, Kaufmann SHE, Nemes E, Scriba TJ, Lauffenburger D, Alter G, Fortune SM. Age and sex influence antibody profiles associated with tuberculosis progression. Nat Microbiol. 2024 Apr 24. doi: 10.1038/s41564-024-01678-x. PMID: 38658786.
  6. Dill-McFarland KA, Simmons JD, Peterson GJ, Nguyen FK, Campo M, Benchek P, Stein CM, Vaisar T, Mayanja-Kizza H, Boom WH, Hawn TR. Epigenetic programming of host lipid metabolism associates with resistance to TST/IGRA conversion after exposure to Mycobacterium tuberculosis. bioRxiv [Preprint]. 2024 Mar 4:2024.02.27.582348. doi: 10.1101/2024.02.27.582348. PMID: 38464296; PMCID: PMC10925331.
  7. Dirajlal-Fargo S, Sattar A, Strah M, Karungi C, Gumikiriza-Onoria JL, Santoro AF, Kirsch C, Nanteza A, Ferraris CM, Tsapalas D, Asiedu N, Funderburg N, Musiime V, McComsey GA, Robbins RN. Immune Activation Is Associated With Neurocognitive Performance in Ugandan Adolescents Living With HIV. J Acquir Immune Defic Syndr. 2024 Nov 1;97(3):296-304. doi: 10.1097/QAI.0000000000003483. PMID: 38902861; PMCID: PMC11493505.
  8. Dirajlal-Fargo S, Strah M, Ailstock K, Sattar A, Karungi C, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA. Factors associated with insulin resistance in a longitudinal study of Ugandan youth with and without HIV. AIDS. 2024 Feb 1;38(2):177-184. doi: 10.1097/QAD.0000000000003741. PMID: 37788113.
  9. Dousa KM, Shin E, Kurz SG, Plummer M, Nantongo M, Bethel CR, Taracila MA, Nguyen DC, Kreiswith BN, Daley CL, Remy KE, Holland SM, Bonomo RA. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024 Jun 12;15(6):e0060924. doi: 10.1128/mbio.00609-24. PMID: 38742824; PMCID: PMC11237399.
  10. Gutierrez J, Nsereko M, Malone LL, Mayanja-Kizza H, Kisingo H, Boom WH, Bark CM, Stein CM. Capturing Recent Mycobacterium tuberculosis Infection by Tuberculin Skin Test vs. Interferon-Gamma Release Assay. Trop Med Infect Dis. 2024 Apr 11;9(4):81. doi: 10.3390/tropicalmed9040081. PMID: 38668542; PMCID: PMC11053984.
  11. Hajihassani O, Zarei M, Roichman A, Loftus A, Boutros CS, Hue J, Naji P, Boyer J, Tahan S, Gallagher P, Beegan W, Choi J, Lei S, Kim C, Rathore M, Nakazzi F, Shah I, Lebo K, Cheng H, Mudigonda A, Alibeckoff S, Ji K, Graor H, Miyagi M, Vaziri-Gohar A, Brunengraber H, Wang R, Lund PJ, Rothermel LD, Rabinowitz JD, Winter JM. A Ketogenic Diet Sensitizes Pancreatic Cancer to Inhibition of Glutamine Metabolism. bioRxiv [Preprint]. 2024 Jul 23:2024.07.19.604377. doi: 10.1101/2024.07.19.604377. PMID: 39211182; PMCID: PMC11361133.
  12. Honeycutt E, Kizito F, Karn J, Sweet T. Direct Analysis of HIV mRNA m6A Methylation by Nanopore Sequencing. Methods Mol Biol. 2024;2807:209-227. doi: 10.1007/978-1-0716-3862-0_15. PMID: 38743231.
  13. Hong H, Dill-McFarland KA, Simmons JD, Peterson GJ, Benchek P, Mayanja-Kizza H, Boom WH, Stein CM, Hawn TR. Mycobacterium tuberculosis-dependent monocyte expression quantitative trait loci, cytokine production, and TB pathogenesis. Front Immunol. 2024 Mar 7;15:1359178. doi: 10.3389/fimmu.2024.1359178. PMID: 38515745; PMCID: PMC10954790.
  14. Kizito F, Nguyen K, Mbonye U, Shukla M, Luttge B, Checkley MA, Agaponova A, Leskov K, Karn J. Structural rearrangements in the nucleus localize latent HIV proviruses to a perinucleolar compartment supportive of reactivation. Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2202003121. doi: 10.1073/pnas.2202003121. PMID: 38669184; PMCID: PMC11067448.
  15. Loftus AW, Zarei M, Kakish H, Hajihassani O, Hue JJ, Boutros C, Graor HJ, Nakazzi F, Bahlibi T, Winter JM, Rothermel LD. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma. Cancer Treat Rev. 2024 Sep;129:102795. doi: 10.1016/j.ctrv.2024.102795. PMID: 38972133; PMCID: PMC11361048.
  16. Lwanga C, Aber P, Tickell KD, Ngari MM, Mukisa J, Atuhairwe M, Brown L, Mupere E, Potani I, Shahrin L, Morgan B, Singa BO, Nankabirwa V, Mugambe RK, Mukasa Z, Walson JL, Berkley JA, Lancioni CL. Impact of HIV exposure without infection on hospital course and mortality among young children in sub-Saharan Africa: a multi-site cohort study. BMC Med. 2024 Dec 3;22(1):573. doi: 10.1186/s12916-024-03790-5. PMID: 39627711; PMCID: PMC11613948.
  17. Mangan JM, Hedges KNC, Salerno MM, Tatum K, Bouwkamp B, Frick MW, McKenna L, Muzanyi G, Engle M, Coetzee J, Yvetot J, Elskamp M, Lamunu D, Tizora MET, Namutamba D, Chaisson RE, Swindells S, Nahid P, Dorman SE, Kurbatova E. Facilitators and barriers to adolescent participation in a TB clinical trial. Int J Tuberc Lung Dis. 2024 May 1;28(5):243-248. doi: 10.5588/ijtld.23.0519. PMID: 38659142.
  18. Nantongo M, Nguyen DC, Bethel CR, Taracila MA, Li Q, Dousa KM, Shin E, Kurz SG, Nguyen L, Kreiswirth BN, Boom WH, Plummer MS, Bonomo RA. Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infect Dis. 2024 May 10;10(5):1767-1779. doi: 10.1021/acsinfecdis.4c00119. PMID: 38619138.
  19. Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM. Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clin Infect Dis. 2024 Mar 11:ciae119. doi: 10.1093/cid/ciae119. PMID: 38462673.
  20. Shin E, Dousa KM, Taracila MA, Bethel CR, Nantongo M, Nguyen DC, Akusobi C, Kurz SG, Plummer MS, Daley CL, Holland SM, Rubin EJ, Bulitta JB, Boom WH, Kreiswirth BN, Bonomo RA. Durlobactam in combination with β-lactams to combat Mycobacterium abscessus. Antimicrob Agents Chemother. 2024 Dec 23:e0117424. doi: 10.1128/aac.01174-24. PMID: 39714147.
  21. Sun M, Phan JM, Kieswetter NS, Huang H, Yu KKQ, Smith MT, Liu YE, Wang C, Gupta S, Obermoser G, Maecker HT, Krishnan A, Suresh S, Gupta N, Rieck M, Acs P, Ghanizada M, Chiou SH, Khatri P, Boom WH, Hawn TR, Stein CM, Mayanja-Kizza H, Davis MM, Seshadri C. Author Correction: Specific CD4+T cell phenotypes associate with bacterial control in people who 'resist' infection with Mycobacterium tuberculosis. Nat Immunol. 2024 Oct;25(10):1976. doi: 10.1038/s41590-024-01959-x. PMID: 39160374; PMCID: PMC11436351.
  22. Windels EM, Wampande EM, Joloba ML, Boom WH, Goig GA, Cox H, Hella J, Borrell S, Gagneux S, Brites D, Stadler T. HIV co-infection is associated with reduced Mycobacterium tuberculosis transmissibility in sub-Saharan Africa. PLoS Pathog. 2024 May 2;20(5):e1011675. doi: 10.1371/journal.ppat.1011675. PMID: 38696531; PMCID: PMC11093396.
  23. Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PP, Nahid P, Dorman SE, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Brown NE, Engle ML, Nhung NV, Nsubuga P, Diacon A, Dooley KE, Chaisson RE, Swindells S, Savic RM; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Pyrazinamide safety, efficacy, and dosing for treating drug-susceptible pulmonary tuberculosis: A Phase 3, randomized, controlled clinical trial. Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165OC. PMID: 39012226.
  24. Zarei M, Hajihassani O, Hue JJ, Loftus AW, Graor HJ, Nakazzi F, Naji P, Boutros CS, Uppin V, Vaziri-Gohar A, Shalaby AS, Asara JM, Rothermel LD, Brody JR, Winter JM. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Cancer Res. 2024 Sep 16;84(18):3072-3085. doi: 10.1158/0008-5472.CAN-23-1895. PMID: 38843355; PMCID: PMC11403292.
  1. Alles M, Gunasena M, Kettelhut A, Ailstock K, Musiime V, Kityo C, Richardson B, Mulhern W, Tamilselvan B, Rubsamen M, Kasturiratna D, Demberg T, Cameron CM, Cameron MJ, Dirajlal-Fargo S, Funderburg NT, Liyanage NPM. Activated NK Cells with Pro-inflammatory Features are Associated with Atherogenesis in Perinatally HIV-Acquired Adolescents. medRxiv [Preprint]. 2023 Nov 7:2023.11.06.23297580. doi: 10.1101/2023.11.06.23297580. PMID: 37986784; PMCID: PMC10659511.
  2. Baluku JB, Namiiro S, Namanda B, Katusabe S, Namusoke D, Nkonge R, Okecha T, Nassaazi C, Niyonzima N, Bogere N, Nuwagira E, Nabwana M, Ssekamatte P, Andia-Biraro I, Worodria W, Salata R, Mfinanga S, Gerson S, Kirenga B. Mycobacterium tuberculosis infection and cytogenetic abnormalities among people with HIV. Mutat Res Genet Toxicol Environ Mutagen. 2023 May-Jun;888:503640. doi: 10.1016/j.mrgentox.2023.503640. PMID: 37188437.
  3. Diallo AH, Mohammad AS, Shahid SB, Khan AF, Saleem AF, Singa BO, Gnoumou BS, Tigoi C, Otieno CA, Bourdon C, Oduol CO, Lancioni CL, Manyasi C, McGrath CJ, Maronga C, Lwanga C, Brals D, Ahmed D, Mondal D, Denno DM, Mangale DI, Chimezi E, Mbale E, Mupere E, Mamun GMS, Ouedraogo I, Githinji G, Berkley JA, Njirammadzi J, Mukisa J, Thitiri J, Haggstrom J, Carreon JD, Walson JL, Jemutai J, Tickell KD, Shahrin L, Mallewa M, Hossain MI, Chisti MJ, Timbwa M, Mburu M, Ngari MM, Ngao N, Aber P, Harawa PP, Sukhtankar P, Bandsma RH, Bamouni RM, Molyneux S, Feldman S, Mwaringa S, Shaima SN, Ali SA, Afsana SM, Banu S, Ahmed T, Voskuijl WP, Kazi Z. Characterising paediatric mortality during and after acute illness in Sub-Saharan Africa and South Asia: a secondary analysis of the CHAIN cohort using a machine learning approach. EClinicalMedicine. 2023 Feb 6;57:101838. doi: 10.1016/j.eclinm.2023.101838. PMID: 36825237; PMCID: PMC9941052.
  4. Dill-McFarland KA, Mitchell K, Batchu S, Segnitz RM, Benson B, Janczyk T, Cox MS, Mayanja-Kizza H, Boom WH, Benchek P, Stein CM, Hawn TR, Altman MC. Kimma: flexible linear mixed effects modeling with kinship covariance for RNA-seq data. Bioinformatics. 2023 May 4;39(5):btad279. doi: 10.1093/bioinformatics/btad279. PMID: 37140544; PMCID: PMC10182851.
  5. Dirajlal-Fargo S, Strah M, Ailstock K, Sattar A, Karungi C, Nazzinda R, Kityo C, Musiime V, Funderburg N, McComsey GA. Persistent immune activation and altered gut integrity over time in a longitudinal study of Ugandan youth with perinatally acquired HIV. Front Immunol. 2023 Mar 28;14:1165964. doi: 10.3389/fimmu.2023.1165964. PMID: 37056779; PMCID: PMC10086119.
  6. Dirajlal-Fargo S, Zhao C, Labbato D, Sattar A, Karungi C, Longenecker CT, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA. Longitudinal Changes in Subclinical Vascular Disease in Ugandan Youth With Human Immunodeficiency Virus. Clin Infect Dis. 2023 Feb 8;76(3):e599-e606. doi: 10.1093/cid/ciac686. PMID: 36004575; PMCID: PMC10169397.
  7. Gail DP, Suzart VG, Du W, Kaur Sandhu A, Jarvela J, Nantongo M, Mwebaza I, Panigrahi S, Freeman ML, Canaday DH, Boom WH, Silver RF, Carpenter SM. Mycobacterium tuberculosis impairs human memory CD4+ T cell recognition of M2 but not M1-like macrophages. iScience. 2023 Aug 23;26(9):107706. doi: 10.1016/j.isci.2023.107706. PMID: 37634140; PMCID: PMC10465958.
  8. Hong H, Dill-McFarland KA, Simmons JD, Peterson GJ, Benchek P, Mayanja-Kizza H, Boom WH, Stein CM, Hawn TR. Mycobacterium tuberculosis-dependent Monocyte Expression Quantitative Trait Loci and Tuberculosis Pathogenesis. medRxiv [Preprint]. 2023 Aug 29:2023.08.28.23294698. doi: 10.1101/2023.08.28.23294698. PMID: 37693490; PMCID: PMC10491362.
  9. Hong H, Dill-Mcfarland KA, Benson B, Simmons JD, Peterson GJ, Benchek P, Stein CM, Boom WH, Mayanja-Kizza H, Hawn TR. Mycobacterium tuberculosis-induced monocyte transcriptional responses associated with resistance to tuberculin skin test/interferon-γ release assay conversion in people with HIV. AIDS. 2023 Dec 1;37(15):2287-2296. doi: 10.1097/QAD.0000000000003729. PMID: 37696247; PMCID: PMC10614631.
  10. Kaawa-Mafigiri D, Nsereko M, Odie M, Johnson JL. Perceptions about and reasons for participation in research bronchoscopy in Uganda: A qualitative analysis. PLoS One. 2023 Oct 20;18(10):e0293174. doi: 10.1371/journal.pone.0293174. PMID: 37862303; PMCID: PMC10588838.
  11. Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. Am J Respir Crit Care Med. 2023 Feb 15;207(4):414-428. doi: 10.1164/rccm.202206-1118OC. PMID: 36790881; PMCID: PMC9974442.
  12. Mbonye U, Kizito F, Karn J. New insights into transcription elongation control of HIV-1 latency and rebound. Trends Immunol. 2023 Jan;44(1):60-71. doi: 10.1016/j.it.2022.11.003. PMID: 36503686; PMCID: PMC10103429.
  13. McHenry ML, Stein CM, Kodaman N, Maro I, Wieland-Alter W, Igo RP Jr, Magohe A, Malone LL, Chervenak K, Hall NB, Matee M, Mayanja-Kizza H, Joloba M, Moore JH, Scott WK, Lahey T, Boom WH, von Reyn CF, Williams SM, Sirugo G. Tuberculosis severity associates with variants and eQTLs related to vascular biology and infection-induced inflammation. PLoS Genet. 2023 Mar;19(3):e1010387. doi: 10.1371/journal.pgen.1010387. PMID: 36972313; PMCID: PMC10079228.
  14. Morrow E, Liu Q, Kiguli S, Swarbrick G, Nsereko M, Null MD, Cansler M, Mayanja-Kizza H, Boom WH, Chheng P, Nyendak MR, Lewinsohn DM, Lewinsohn DA, Lancioni CL. Production of Proinflammatory Cytokines by CD4+ and CD8+ T Cells in Response to Mycobacterial Antigens among Children and Adults with Tuberculosis. Pathogens. 2023 Nov 14;12(11):1353. doi: 10.3390/pathogens12111353. PMID: 38003817; PMCID: PMC10675744.
  15. Mwebaza I, Shaw R, Li Q, Fletcher S, Achkar JM, Harding CV, Carpenter SM, Boom WH. Impact of Mycobacterium tuberculosis Glycolipids on the CD4+ T Cell-Macrophage Immunological Synapse. J Immunol. 2023 Nov 1;211(9):1385-1396. doi: 10.4049/jimmunol.2300107. PMID: 37695687; PMCID: PMC10579150.
  16. Nakandi BT, Muhimbise O, Djuhadi A, Mulerwa M, McGrath J, Makobore PN, Rollins AM, Ssekitoleko RT. Experiences of medical device innovators as they navigate the regulatory system in Uganda. Front Med Technol. 2023 Apr 27;5:1162174. doi: 10.3389/fmedt.2023.1162174. PMID: 37181098; PMCID: PMC10172494.
  17. Nyiro B, Amanya SB, Bayiyana A, Wasswa F, Nabulime E, Kayongo A, Nankya I, Mboowa G, Kateete DP, Sande OJ. Reduced CCR5 expression among Uganda HIV controllers. Retrovirology. 2023 May 25;20(1):8. doi: 10.1186/s12977-023-00626-7. PMID: 37231494; PMCID: PMC10210444.
  18. Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 Feb 8;76(3):e580-e589. doi: 10.1093/cid/ciac707. PMID: 36041016; PMCID: PMC10169427.
  19. Simmons JD, Segnitz RM, Dill-McFarland KA, Stein CM, Peterson GJ, Mayanja-Kizza H, Boom WH, Hawn TR. Differentially expressed transcript isoforms associate with resistance to tuberculin skin test and interferon gamma release assay conversion. PLoS One. 2023;18(4):e0284498. doi: 10.1371/journal.pone.0284498. PMID: 37058459; PMCID: PMC10104279.

  20. Stein CM, Hall NB, Malone LL, Mupere E. The household contact study design for genetic epidemiological studies of infectious diseases. Front Genet. 2013 Apr 30;4:61. doi: 10.3389/fgene.2013.00061. PMID: 23641253; PMCID: PMC3639375.

  21. Tao L, Zalwango S, Chervenak K, Thiel B, Malone LL, Qiu F, Mayanja-Kizza H, Boom WH, Stein CM. Genetic and Shared Environmental Influences on Interferon-gamma Production in Response to Mycobacterium tuberculosis Antigens in a Ugandan Population. Am J Trop Med Hyg. 2013.

  22. Toossi Z, Funderburg NT, Sirdeshmuk S, Whalen CC, Nanteza MW, Johnson DF, Mayanja-Kizza H, Hirsch CS. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects. J Infect Dis. 2013 Jun 15;207(12):1841-9. doi: 10.1093/infdis/jit092. PMID: 23479321; PMCID: PMC3654743.

  23. Wampande EM, Mupere E, Debanne SM, Asiimwe BB, Nsereko M, Mayanja H, Eisenach K, Kaplan G, Boom HW, Sebastien G, Joloba ML. Long-term dominance of Mycobacterium tuberculosis Uganda family in peri-urban Kampala-Uganda is not associated with cavitary disease. BMC Infect Dis. 2013;13(1):484.

  24. Winchester MS, McGrath JW, Kaawa-Mafigiri D, Namutiibwa F, Ssendegye G, Nalwoga A, Kyarikunda E, Birungi J, Kisakye S, Ayebazibwe N, Walakira E, Rwabukwali CB. Early HIV disclosure and nondisclosure among men and women on antiretroviral treatment in Uganda. AIDS Care. 2013;25(10):1253-8. doi: 10.1080/09540121.2013.764386. PMID: 23356654; PMCID: PMC3657329.

  1. Auma AWN, Kowal C, Shive CL, Lange A, Damjanovska S, Zebrowski E, Reyes E, Calabrese L, Kostadinova L, Falck-Ytter Y, Mattar M, Anthony DD. Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy. PLoS One. 2022 Apr 28;17(4):e0267512. doi: 10.1371/journal.pone.0267512. PMID: 35482664; PMCID: PMC9049346.
  2. Bark C, Nsereko MN, Kiwanuka N, Whalen CC, Stein CM, Boom H, Mayanja-Kizza H, Nalukwago S, Kakaire R, Jingo JK, Paramithiotis E. 336. Developing a Protein Signature of Early Latent Tuberculosis Infection. Open Forum Infect Dis. 2022 Dec 15;9(Suppl 2):ofac492.414. doi: 10.1093/ofid/ofac492.414. PMCID: PMC9752230.
  3. Chang AY, Rwebembera J, Bendavid E, Okello E, Barry M, Beaton AZ, Haeffele C, Webel AR, Kityo C, Longenecker CT. Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living With Human Immunodeficiency Virus (HIV) and Rheumatic Heart Disease in Uganda. Clin Infect Dis. 2022 May 3;74(9):1543-1548. doi: 10.1093/cid/ciab681. PMID: 34382644.
  4. Dawkins BA, Garman L, Cejda N, Pezant N, Rasmussen A, Rybicki BA, Levin AM, Benchek P, Seshadri C, Mayanja-Kizza H, Iannuzzi MC, Stein CM, Montgomery CG. Novel HLA associations with outcomes of Mycobacterium tuberculosis exposure and sarcoidosis in individuals of African ancestry using nearest-neighbor feature selection. Genet Epidemiol. 2022 Oct;46(7):463-474. doi: 10.1002/gepi.22490. PMID: 35702824; PMCID: PMC10237150.
  5. Inzaule SC, Kroeze S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Steegen K, Nankya I, Boender TS, Ondoa P, Sigaloff KCE, de Wit TFR, Hamers RL. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis. AIDS. 2022 Aug 1;36(10):1437-1447. doi: 10.1097/QAD.0000000000003270. PMID: 35608116.
  6. Joussef-Piña S, Nankya I, Nalukwago S, Baseke J, Rwambuya S, Winner D, Kyeyune F, Chervenak K, Thiel B, Asaad R, Dobrowolski C, Luttge B, Lawley B, Kityo CM, Boom WH, Karn J, Quiñones-Mateu ME. Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda. Retrovirology. 2022 Jan 15;19(1):1. doi: 10.1186/s12977-022-00587-3. PMID: 35033105; PMCID: PMC8760765.
  7. Longenecker CT, Bogorodskaya M, Margevicius S, Nazzinda R, Bittencourt MS, Erem G, Nalukwago S, Huaman MA, Ghoshhajra BB, Siedner MJ, Juchnowski SM, Zidar DA, McComsey GA, Kityo C. Sex modifies the association between HIV and coronary artery disease among older adults in Uganda. J Int AIDS Soc. 2022 Jan;25(1):e25868. doi: 10.1002/jia2.25868. PMID: 34995413; PMCID: PMC8741262.
  8. Milad M, Karungi C, Sattar A, Musiime V, Nazzinda R, McComsey GA, Dirajlal-Fargo S. Impact of COVID-19 on Well-Being and Physical Activity in Ugandan Children With and Without HIV. J Phys Act Health. 2022 Aug 4;19(9):638-641. doi: 10.1123/jpah.2022-0061. PMID: 35926844.
  9. Njunge JM, Tickell K, Diallo AH, Sayeem Bin Shahid ASM, Gazi MA, Saleem A, Kazi Z, Ali S, Tigoi C, Mupere E, Lancioni CL, Yoshioka E, Chisti MJ, Mburu M, Ngari M, Ngao N, Gichuki B, Omer E, Gumbi W, Singa B, Bandsma R, Ahmed T, Voskuijl W, Williams TN, Macharia A, Makale J, Mitchel A, Williams J, Gogain J, Janjic N, Mandal R, Wishart DS, Wu H, Xia L, Routledge M, Gong YY, Espinosa C, Aghaeepour N, Liu J, Houpt E, Lawley TD, Browne H, Shao Y, Rwigi D, Kariuki K, Kaburu T, Uhlig HH, Gartner L, Jones K, Koulman A, Walson J, Berkley J. The Childhood Acute Illness and Nutrition (CHAIN) network nested case-cohort study protocol: a multi-omics approach to understanding mortality among children in sub-Saharan Africa and South Asia. Gates Open Res. 2022 Nov 3;6:77. doi: 10.12688/gatesopenres.13635.2. PMID: 36415883; PMCID: PMC9646488.
  10. Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clin Infect Dis. 2022 Aug 30:ciac707. PMID: 36041016.
  11. Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips PPJ, Bryant K, Scott N, Vernon A, Kurbatova EV, Chaisson RE, Dorman SE, Nahid P, Swindells S, Dooley KE, Fletcher CV. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 Sep 10;75(4):560-566. PMID: 34918028.
  12. Shukla M, Kizito F, Mbonye U, Nguyen K, Dobrowolski C, Karn J. A Reliable Primary Cell Model for HIV Latency: The QUECEL (Quiescent Effector Cell Latency) Method. Methods Mol Biol. 2022;2407:57-68. doi: 10.1007/978-1-0716-1871-4_5. PMID: 34985657.
  13. Simmons JD, Dill-McFarland KA, Stein CM, Van PT, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Benchek P, Nsereko M, Velen K, Fielding KL, Grant AD, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte Transcriptional Responses to Mycobacterium tuberculosis Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. mSphere. 2022 Jun 29;7(3):e0015922. doi: 10.1128/msphere.00159-22. PMID: 35695527; PMCID: PMC9241521.
  14. Toe S, Nagy M, Albar Z, Yu J, Sattar A, Nazzinda R, Musiime V, Etajak S, Walyawula F, McComsey GA, Atuyambe LM, Dirajlal-Fargo S. Ambient air pollution is associated with vascular disease in Ugandan HIV-positive adolescents. AIDS. 2022 May 1;36(6):863-870. doi: 10.1097/QAD.0000000000003186. PMID: 35131961; PMCID: PMC9081159.
  15. Uebelhoer LS, Gwela A, Thiel B, Nalukwago S, Mukisa J, Lwanga C, Getonto J, Nyatichi E, Dena G, Makazi A, Mwaringa S, Mupere E, Berkley JA, Lancioni CL. Toll-Like receptor-induced immune responses during early childhood and their associations with clinical outcomes following acute illness among infants in Sub-Saharan Africa. Front Immunol. 2022 Feb 3;12:748996. doi: 10.3389/fimmu.2021.748996. PMID: 35185860; PMCID: PMC8850627.
  1. Auma AWN, Shive C, Damjanovska S, Kowal C, Cohen DE, Bhattacharya D, Alston-Smith B, Osborne M, Kalayjian R, Balagopal A, Sulkowski M, Wyles D, Anthony DD. T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy. Open Forum Infect Dis. 2021 Feb 18;8(4):ofab079. doi: 10.1093/ofid/ofab079. PMID: 33880389; PMCID: PMC8043262.
  2. Auma AWN, Shive CL, Kostadinova L, Anthony DD. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection. Viruses. 2021 Dec 29;14(1):50. doi: 10.3390/v14010050. PMID: 35062255; PMCID: PMC8780994.
  3. Auma AWN, Shive CL, Lange A, Damjanovska S, Kowal C, Zebrowski E, Pandiyan P, Wilson B, Kalayjian RC, Canaday DH, Anthony DD. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons. Front Immunol. 2021 Apr 12;12:641230. doi: 10.3389/fimmu.2021.641230. PMID: 33912168; PMCID: PMC8075159.
  4. Campo M, Heater S, Peterson GJ, Simmons JD, Skerrett SJ, Mayanja-Kizza H, Stein CM, Boom WH, Hawn TR. HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2021 Mar;127:102062. doi: 10.1016/j.tube.2021.102062. PMID: 33639591; PMCID: PMC8650124.
  5. Dirajlal-Fargo S, Sattar A, Yu J, Albar Z, Chaves FC, Riedl K, Kityo C, Bowman E, McComsey GA, Funderburg N. Lipidome association with vascular disease and inflammation in HIV+ Ugandan children. AIDS. 2021 Aug 1;35(10):1615-1623. doi: 10.1097/QAD.0000000000002923. PMID: 33878042; PMCID: PMC8286331.
  6. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott N, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360; PMCID: PMC8282329.
  7. Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Ballena I, Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Farquhar C, Hawn TR, Sterling TR, Fichtenbaum CJ, Longenecker CT. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clin Infect Dis. 2021 Nov 2;73(9):e3384-e3390. doi: 10.1093/cid/ciaa1934. PMID: 33388766; PMCID: PMC8563179.
  8. Huaman MA, Feria MG, Kityo C, Nalukwago S, Nazzinda R, Zidar DA, Zanni MV, Siedner MJ, Grinspoon SK, Longenecker CT. A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. Viruses. 2021 Oct 22;13(11):2135. doi: 10.3390/v13112135. PMID: 34834941; PMCID: PMC8620269.
  9. Huaman MA, Juchnowski SM, Zidar DA, Kityo CM, Nalukwago S, Nazzinda R, Fichtenbaum CJ, Longenecker CT. Monocyte activation in persons living with HIV and tuberculosis coinfection. AIDS. 2021 Mar 1;35(3):447-452. doi: 10.1097/QAD.0000000000002766. PMID: 33252496; PMCID: PMC7855758.
  10. Mafigiri DK, Iradukunda C, Atumanya C, Odie M, Mancuso A, Tran N, McGrath J, Luzze H. A qualitative study of the development and utilization of health facility-based immunization microplans in Uganda. Health Res Policy Syst. 2021 Aug 11;19(Suppl 2):52. doi: 10.1186/s12961-021-00708-y. PMID: 34380523; PMCID: PMC8356367.
  11. McHenry ML, Benchek P, Malone L, Nsereko M, Mayanja-Kizza H, Boom WH, Williams SM, Hawn TR, Stein CM. Resistance to TST/IGRA conversion in Uganda: Heritability and Genome-Wide Association Study. EBioMedicine. 2021 Dec;74:103727. doi: 10.1016/j.ebiom.2021.103727. PMID: 34871961; PMCID: PMC8652006.
  12. McHenry ML, Wampande EM, Joloba ML, Malone LL, Mayanja-Kizza H, Bush WS, Boom WH, Williams SM, Stein CM. Interaction between M. Tuberculosis Lineage and Human Genetic Variants Reveals Novel Pathway Associations with Severity of TB. Pathogens. 2021 Nov 15;10(11):1487. doi: 10.3390/pathogens10111487. PMID: 34832643; PMCID: PMC8617877.
  13. Ndashimye E, Avino M, Olabode AS, Poon AFY, Gibson RM, Li Y, Meadows A, Tan C, Reyes PS, Kityo CM, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. J Antimicrob Chemother. 2021 Dec 1;76(12):3525-3533. doi: 10.1093/jac/dkaa355. PMID: 34453542; PMCID: PMC8521396.
  14. Stein CM, Mayanja-Kizza H, Hawn TR, Boom WH. Importance of Study Design and Phenotype Definition in Ongoing Studies of Resistance to Latent Mycobacterium tuberculosis Infection. The Journal of infectious diseases. 2020;221(6):1025-6. doi: 10.1093/infdis/jiz544. PMID: 31605501; PMCID: PMC7049549.
  15. Swarbrick GM, Gela A, Cansler ME, Null MD, Duncan RB, Nemes E, Shey M, Nsereko M, Mayanja-Kizza H, Kiguli S, Koh J, Hanekom WA, Hatherill M, Lancioni C, Lewinsohn DM, Scriba TJ, Lewinsohn DA. Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. Front Immunol. 2021 Sep 16;12:748996. doi: 10.3390/pathogens10111487. PMID: 34832643; PMCID: PMC8617877.
  1. Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. AIDS Res Ther. 2020;17(1):2. doi: 10.1186/s12981-019-0257-8. PMID: 31915033; PMCID: PMC6950878.
  2. Bajunirwe F, Ayebazibwe N, Mulogo E, Eng M, McGrath J, Kaawa-Mafigiri D, Mugyenyi P, Sethi AK. Effectiveness of a mobile antiretroviral pharmacy and HIV care intervention on the continuum of HIV care in rural Uganda. AIDS Care. 2020 Sep;32(9):1111-1115. doi: 10.1080/09540121.2020.1753006. PMID: 32279527.
  3. McHenry ML, Bartlett J, Igo RP Jr, Wampande EM, Benchek P, Mayanja-Kizza H, Fluegge K, Hall NB, Gagneux S, Tishkoff SA, Wejse C, Sirugo G, Boom WH, Joloba M, Williams SM, Stein CM. Interaction between host genes and Mycobacterium tuberculosis lineage can affect tuberculosis severity: Evidence for coevolution? PLoS Genet. 2020 Apr 30;16(4):e1008728. doi: 10.1371/journal.pgen.1008728. PMID: 32352966; PMCID: PMC7217476.
  4. Ndashimye E, Avino M, Olabode AS, Poon AFY, Gibson RM, Li Y, Meadows A, Tan C, Reyes PS, Kityo CM, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. J Antimicrob Chemother. 2020 Dec 1;75(12):3525-3533. doi: 10.1093/jac/dkaa355. PMID: 32853364; PMCID: PMC7662175.
  5. Stein CM, Mayanja-Kizza H, Hawn TR, Boom WH. Importance of Study Design and Phenotype Definition in Ongoing Studies of Resistance to Latent Mycobacterium tuberculosis Infection. The Journal of infectious diseases. 2020;221(6):1025-6. doi: 10.1093/infdis/jiz544. PMID: 31605501; PMCID: PMC7049549.
  6. Swarbrick GM, Gela A, Cansler ME, Null MD, Duncan RB, Nemes E, Shey M, Nsereko M, Mayanja-Kizza H, Kiguli S, Koh J, Hanekom WA, Hatherill M, Lancioni C, Lewinsohn DM, Scriba TJ, Lewinsohn DA. Postnatal Expansion, Maturation, and Functionality of MR1T Cells in Humans. Front Immunol. 2021 Sep 16;12:748996. doi: 10.3390/pathogens10111487. PMID: 34832643; PMCID: PMC8617877.
  1. Smith KC, Kibwana S, Mbatidde M, Nagata E, Kyle S. Uganda Capacity Program: Strengthening health professional training institutions as a sustainable approach to improving healthcare Human Resources for Health. 2019.
  2. Baluku JB, Nassozi S, Kizza D, Katagira W, Ssinabulya I, Nakwagala FN, Worodria W. Prevalence of pulmonary hypertension and associated factors in patients with heart failure at Uganda Heart Institute. BMC Cardiovasc Disord. 2019;19(1):77. doi: 10.1186/s12872-019-1059-6. PMID: 30940093. PMCID: PMC6444636.
  3. Matovu JKB, Kabwama SN, Ssekamatte T, Ssenfuka F, Wanyenze RK. COVID-19 Awareness, Adoption of COVID-19 Preventive Measures, and Effects of COVID-19 Lockdown Among Adolescent Boys and Young Men in Kampala, Uganda. J Community Health. 2019.
  1. Ellis J, Oyella J, Bazira J, and Sarah Kiguli S. Challenges and Opportunities in Implementing a Competency Based Medical Education Curriculum at Makerere University College of Health Sciences, Kampala, Uganda. Ann Glob Health. 2018; 84(1): 188, 1–12. DOI: https://doi.org/10.29024/aogh.31.
  2. Ogwang M, Bateganya M, Wandabwa M, Mugerwa H, Teguzirigwa J, Kalyesubula I, Walusansa V, Nabunnya Y, Lusiba E, Bahizi G, Kato S, Arinaitwe C, Akello C, Kansestrime K, Zikusooka A, Driciru E, Arem H. Telecommunication for Palliative Care: A New Frontier for Global Health. Studies in Health Technol Inform 2018 Feb; 254:9-13. PMID: 29629721.
  3. Kakande E, Kalungi A, Mwesiga EK, Nanyunja C, Joloba ML, Kaddumukasa M, Wamala S, Ssemogerere L. Multiple Organ Dysfunction Syndrome in Severe COVID-19. Int J Surg Educ. 2018 Sep 12;12(12):11-20. doi:10.1097/ij.2018.023342. PMID: 30293881.
  4. Kakooza-Mwesige A, Andrews C, Peterson S, Wabwire Mangen F, Eliasson AC, Forssberg H. Prevalence of cerebral palsy in Uganda: a population-based study. Lancet Glob Health. 2018 Jan;5(12):e1275-e1282. doi: 10.1016/S2214-109X(17)30374-1. Epub 2017 Oct 24. PMID: 29102350.
  5. Kisaakye E, Ario AR, Bainomugisha K, Cossaboom CM, Lowe D, Bulage L, Kadobera D, Sekamatte M, Lubwama B, Tumusiime D, Tusiime P, Downing R, Nakiire L, Nyakarahuka L, Kyazze S, Wetaka MM, Cardemil CV, Buule J, Mabumba E, Makumbi I, Harris JR, Zhu B-P. Containment of a rift valley fever outbreak in humans and cattle in Uganda, 2018. Int J Infect Dis.2018;101:476. doi:10.1016/j.ijid.2018.05.037.
  6. Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients. Antimicrob Agents Chemother. 2018 Feb 23;60(8):4896-900. doi: 10.1128/AAC.00714-16. PMID: 27270278. PMCID: PMC4958221.
  1. Ploss B, Douglas TS, Glucksberg M, Kaufmann EE, Malkin RA, McGrath J, Mkandawire T, Oden M, Osuntoki A, Rollins A, Sienko K, Ssekitoleko RT, Reichert W. Part II: U.S.-Sub-Saharan Africa Educational Partnerships for Medical Device Design. Ann Biomed Eng. 2017 Nov;45(11):2489-2493. doi: 10.1007/s10439-017-1898-1. PMID: 28812166.
  2. Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2. PMID: 28124478. PMCID: PMC5545752.
  3. Seshadri C, Sedaghat N, Campo M, Peterson G, Wells RD, Olson GS, Sherman DR, Stein CM, Mayanja-Kizza H, Shojaie A, Boom WH, Hawn TR; Tuberculosis Research Unit (TBRU). Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection. PLoS One. 2017 Apr 17;12(4):e0175844. doi: 10.1371/journal.pone.0175844. PMID: 28414762. PMCID: PMC5393882.
  4. Sobota RS, Stein CM, Kodaman N, Maro I, Wieland-Alter W, Igo RP Jr, Magohe A, Malone LL, Chervenak K, Hall NB, Matee M, Mayanja-Kizza H, Joloba M, Moore JH, Scott WK, Lahey T, Boom WH, von Reyn CF, Williams SM, Sirugo G. A chromosome 5q31.1 locus associates with tuberculin skin test reactivity in HIV-positive individuals from tuberculosis hyper-endemic regions in east Africa. PLoS Genet. 2017 Jun 19;13(6):e1006710. doi: 10.1371/journal.pgen.1006710. PMID: 28628665. PMCID: PMC5495514.
  5. Stein CM, Sausville L, Wejse C, Sobota RS, Zetola NM, Hill PC, Boom WH, Scott WK, Sirugo G, Williams SM. Genomics of human pulmonary tuberculosis: from genes to pathways. Curr Genet Med Rep. 2017 Dec;5(4):149-166. doi: 10.1007/s40142-017-0130-9. Epub 2017 Oct 12. PMID: 29805915. PMCID: PMC5965286.
  6. Winchester MS, McGrath JW, Kaawa-Mafigiri D, Namutiibwa F, Ssendegye G, Nalwoga A, Kyarikunda E, Birungi J, Kisakye S, Ayebazibwe N, Walakira EJ, Rwabukwali C. Routines, Hope, and Antiretroviral Treatment among Men and Women in Uganda. Med Anthropol Q. 2017 Jun;31(2):237-256. doi: 10.1111/maq.12301. Epub 2016 Aug 21. PMID: 27159357. PMCID: PMC5102816.
  1. 121. Ploss B, Douglas TS, Glucksberg M, Kaufmann EE, Malkin RA, McGrath J, Mkandawire T, Oden M, Osuntoki A, Rollins A, Sienko K, Ssekitoleko RT, Reichert W. Part II: U.S.-Sub-Saharan Africa Educational Partnerships for Medical Device Design. Ann Biomed Eng. 2017 Nov;45(11):2489-2493. doi: 10.1007/s10439-017-1898-1. PMID: 28812166
  1. Buteme HK, Axelsson-Robertson R, Benson L, Joloba ML, Boom WH, Kallenius G, Maeurer M. Human leukocyte antigen class 1 genotype distribution and analysis in persons with active tuberculosis and household contacts from Central Uganda. BMC Infect Dis. 2016;16(1):504.
  2. Guzzo MB, Nguyen HT, Pham TH, Wyszczelska-Rokiel M, Jakubowski H, Wolff KA, Ogwang S, Timpona JL, Gogula S, Jacobs MR, Ruetz M, Kräutler B, Jacobsen DW, Zhang GF, Nguyen L. Methylfolate Trap Promotes Bacterial Thymineless Death by Sulfa Drugs. PLoS Pathog. 2016 Oct 19;12(10):e1005949. doi: 10.1371/journal.ppat.1005949. PMID: 27760199. PMCID: PMC5070874.
  3. Hirsch CS, Rojas R, Wu M, Toossi Z. Mycobacterium tuberculosis Induces Expansion of Foxp3 Positive CD4 T-cells with a Regulatory Profile in Tuberculin Non-sensitized Healthy Subjects: Implications for Effective Immunization against TB. J Clin Cell Immunol. 2016;7(3).
  4. Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. PMID: 27001818. PMCID: PMC4879357.
  5. Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugyenyi PN. HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda. AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11. PMID: 26723018. PMCID: PMC4931746.
  6. Meng Q, Canaday DH, McDonald DJ, Mayanja-Kizza H, Baseke J, Toossi Z. Productive HIV-1 infection is enriched in CD4(-)CD8(-) double negative (DN) T cells at pleural sites of dual infection with HIV and Mycobacterium tuberculosis. Arch Virol. 2016;161(1):181-7.
  7. Sande OJ, Karim AF, Li Q, Ding X, Harding CV, Rojas RE, Boom WH. Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4+ T Cell Anergy via GRAIL. J Immunol. 2016 Jan 15;196(2):691-702. doi: 10.4049/jimmunol.1500710. Epub 2015 Dec 14. PMID: 26667170. PMCID: PMC4707121.
  8. Sobota RS, Stein CM, Kodaman N, Scheinfeldt LB, Maro I, Wieland-Alter W, Igo RP Jr, Magohe A, Malone LL, Chervenak K, Hall NB, Modongo C, Zetola N, Matee M, Joloba M, Froment A, Nyambo TB, Moore JH, Scott WK, Lahey T, Boom WH, von Reyn CF, Tishkoff SA, Sirugo G, Williams SM. A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals. Am J Hum Genet. 2016 Mar 3;98(3):514-524. doi: 10.1016/j.ajhg.2016.01.015. PMID: 26942285. PMCID: PMC4800052.
  9. Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Boom WH, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31. PMID: 27798628; PMCID: PMC5238942.
  10. Venner CM, Nankya I, Kyeyune F, Demers K, Kwok C, Chen PL, Rwambuya S, Munjoma M, Chipato T, Byamugisha J, Van Der Pol B, Mugyenyi P, Salata RA, Morrison CS, Arts EJ. Infecting HIV-1 Subtype Predicts Disease Progression in Women of Sub-Saharan Africa. EBioMedicine. 2016 Nov;13:305-314. doi: 10.1016/j.ebiom.2016.10.014. Epub 2016 Oct 12. PMID: 27751765; PMCID: PMC5264310.
  11. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Hussey GD, Abrahams D, Kafaar F, Hawkridge T, Verver S, Hughes EJ, Ota M, Sutherland J, Howe R, Dockrell HM, Boom WH, Thiel B, Ottenhoff THM, Mayanja-Kizza H, Crampin AC, Downing K, Hatherill M, Valvo J, Shankar S, Parida SK, Kaufmann SHE, Walzl G, Aderem A, Hanekom WA; ACS and GC6-74 cohort study groups. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016 Jun 4;387(10035):2312-2322. doi: 10.1016/S0140-6736(15)01316-1. Epub 2016 Mar 24. PMID: 27017310; PMCID: PMC5392204.
  1. Bagaya BS, Vega JF, Tian M, Nickel GC, Li Y, Krebs KC, Arts EJ, Gao Y. Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. Retrovirology. 2015 May 23;12:44. doi: 10.1186/s12977-015-0170-8. PMID: 25997955; PMCID: PMC4445978.
  2. Canaday DH, Sridaran S, Van Epps P, Aung H, Burant CJ, Nsereko M, Mayanja-Kizza H, Betts MR, Toossi Z. CD4+ T cell polyfunctional profile in HIV-TB coinfection are similar between individuals with latent and active TB infection. Tuberculosis (Edinb). 2015 Jul;95(4):470-5. doi: 10.1016/j.tube.2014.12.008. Epub 2015 Jan 7. PMID: 25956974; PMCID: PMC4475423.
  3. Chheng P, Nsereko M, Malone LL, Okware B, Zalwango S, Joloba M, Boom WH, Mupere E, Stein CM. Tuberculosis case finding in first-degree relative contacts not living with index tuberculosis cases in Kampala, Uganda. Clin Epidemiol. 2015;7:411-9.
  4. Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210. PMID: 25489785; PMCID: PMC5447287.
  5. Ezeamama AE, Mupere E, Oloya J, Martinez L, Kakaire R, Yin X, Sekandi JN, Whalen CC. Age, sex, and nutritional status modify the CD4+ T-cell recovery rate in HIV-tuberculosis co-infected patients on combination antiretroviral therapy. Int J Infect Dis. 2015 Jun;35:73-9. doi: 10.1016/j.ijid.2015.04.008. Epub 2015 Apr 21. PMID: 25910854; PMCID: PMC4497838.
  6. Hall NB, Igo RP Jr, Malone LL, Truitt B, Schnell A, Tao L, Okware B, Nsereko M, Chervenak K, Lancioni C, Hawn TR, Mayanja-Kizza H, Joloba ML, Boom WH, Stein CM; Tuberculosis Research Unit (TBRU). Polymorphisms in TICAM2 and IL1B are associated with TB. Genes Immun. 2015 Mar;16(2):127-133. doi: 10.1038/gene.2014.77. Epub 2014 Dec 18. PMID: 25521228; PMCID: PMC4352113.
  7. Harausz E, Lusiba JK, Nsereko M, Johnson JL, Toossi Z, Ogwang S, Boom WH, Joloba ML. Comparison of MGIT and Myco/F Lytic Liquid-Based Blood Culture Systems for Recovery of Mycobacterium tuberculosis from Pleural Fluid. J Clin Microbiol. 2015;53(4):1391-4.
  8. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P; Tuberculosis Trials Consortium. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015 Jul;95(4):415-20. doi: 10.1016/j.tube.2015.04.011. Epub 2015 May 9. PMID: 26022314; PMCID: PMC4521594.
  9. Kayima J, Nankabirwa J, Sinabulya I, Nakibuuka J, Zhu X, Rahman M, et al. Determinants of hypertension in a young adult Ugandan population in epidemiological transition-the MEPI-CVD survey. BMC Public Health. 2015;15:830.
  10. Kayima J, Nyakoojo W, Nakanjako D, Costa MA, Longenecker CT, Simon DI. Acute Spontaneous Coronary Artery Thrombosis as Initial Presentation of HIV Infection in a Young Man. Case Rep Cardiol. 2015;2015:342348.
  11. Lemonovich TL, Watkins RR, Morrison CS, Kwok C, Chipato T, Musoke R, Arts EJ, Nankya I, Salata RA. Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women. J Int Assoc Provid AIDS Care. 2015 Sep-Oct;14(5):415-22. doi: 10.1177/2325957413504827. Epub 2013 Oct 8. PMID: 24106054; PMCID: PMC4511722.
  12. Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O. Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses. 2015;31(4):421-7.
  13. Meng Q, Canaday DH, McDonald DJ, Mayanja-Kizza H, Baseke J, Toossi Z. Productive HIV-1 infection is enriched in CD4CD8 double negative (DN) T cells at pleural sites of dual infection with HIV and Mycobacterium tuberculosis. Arch Virol. 2015.
  14. Nankya IL, Tebit DM, Abraha A, Kyeyune F, Gibson R, Jegede O, Nickel G, Arts EJ. Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usage. AIDS Res Ther. 2015;12:34.
  15. Ogwang S, Good CE, Okware B, Nsereko M, Jacobs MR, Boom WH, Bark CM. Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis. Antimicrob Agents Chemother. 2015;59(9):5844-6.
  16. Ogwang S, Mubiri P, Bark CM, Joloba ML, Boom WH, Johnson JL. Incubation time of Mycobacterium tuberculosis complex sputum cultures in BACTEC MGIT 960: 4 weeks of negative culture is enough for physicians to consider alternative diagnoses. Diagn Microbiol Infect Dis. 2015;83(2):162-4.
  17. Rausch JW, Tian M, Li Y, Angelova L, Bagaya BS, Krebs KC, Qian F, Zhu C, Arts EJ, Le Grice SF, Gao Y. SiRNA-induced mutation in HIV-1 polypurine tract region and its influence on viral fitness. PLoS One. 2015 Apr 10;10(4):e0122953. doi: 10.1371/journal.pone.0122953. PMID: 25860884; PMCID: PMC4393142.
  18. Toossi Z, Meng Q, Aung H, Liu S, Mayanja-Kizza H, Hirsch CS. Short Communication: Expression of APOBEC3G and Interferon Gamma in Pleural Fluid Mononuclear Cells from HIV/TB Dual Infected Subjects. AIDS Res Hum Retroviruses. 2015;31(7):692-5.
  19. Van Epps P, Sridaran S, Aung H, Wilson BM, Burant CJ, Nserko M, Mayanja-Kizza H, Betts MR, Toossi Z, Canaday DH. CD4 T-cell cytokine correlates of diagnostic tests for latent tuberculous infection in HIV-1-infected subjects. Int J Tuberc Lung Dis. 2015;19(8):927-35.
  20. Wampande EM, Hatzios SK, Achan B, Mupere E, Nsereko M, Mayanja HK, Eisenach K, Boom WH, Gagneux S, Joloba ML; Tuberculosis Research Unit. A single-nucleotide-polymorphism real-time PCR assay for genotyping of Mycobacterium tuberculosis complex in peri-urban Kampala. BMC Infect Dis. 2015 Sep 30;15:396. doi: 10.1186/s12879-015-1121-7. PMID: 26423522; PMCID: PMC4590274.
  21. Wampande EM, Mupere E, Jaganath D, Nsereko M, Mayanja HK, Eisenach K, Boom WH, Gagneux S, Joloba ML; Tuberculosis Research Unit. Distribution and transmission of Mycobacterium tuberculosis complex lineages among children in peri-urban Kampala, Uganda. BMC Pediatr. 2015 Sep 30;15:140. doi: 10.1186/s12887-015-0455-z. PMID: 26424324; PMCID: PMC4588907.
  22. Wandera B, Tumwesigye NM, Nankabirwa JI, Kambugu AD, Parkes-Ratanshi R, Mafigiri DK, Kapiga S, Sethi AK. Alcohol Consumption among HIV-Infected Persons in a Large Urban HIV Clinic in Kampala Uganda: A Constellation of Harmful Behaviors. PLoS One. 2015 May 11;10(5):e0126236. doi: 10.1371/journal.pone.0126236. PMID: 25962171; PMCID: PMC4427399.
  1. Heilig CM, Feng PJ, Joloba ML, Johnson JL, Morgan K, Gitta P, Boom WH, Mayanja-Kizza H, Eisenach KD, Bozeman L, Goldberg SV. How we determined the most reliable solid medium for studying treatment of tuberculosis. Tuberculosis (Edinb). 2014 May;94(3):317-22. doi: 10.1016/j.tube.2014.02.006. Epub 2014 Mar 4. PMID: 24661816; PMCID: PMC4070601.
  2. Jaganath D, Walker AS, Ssali F, Musiime V, Kiweewa F, Kityo C, Salata R, Mugyenyi P, Trial D, Trial A. HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. AIDS Res Hum Retroviruses. 2014;30(6):523-30.
  3. Johnson DF, Malone LL, Zalwango S, Mukisa Oketcho J, Chervenak KA, Thiel B, Mayanja-Kizza H, Stein CM, Boom WH, Lancioni CL; Tuberculosis Research Unit. Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection. PLoS One. 2014 May 5;9(5):e96613. doi: 10.1371/journal.pone.0096613. PMID: 24796677; PMCID: PMC4010490.
  4. Joloba ML, Johnson JL, Feng PJ, Bozeman L, Goldberg SV, Morgan K, Gitta P, Boom HW, Heilig CM, Mayanja-Kizza H, Eisenach KD. What is the most reliable solid culture medium for tuberculosis treatment trials? Tuberculosis (Edinb). 2014;94(3):311-6.
  5. Kagaayi J, Gray RH, Whalen C, Fu P, Neuhauser D, McGrath JW, Sewankambo NK, Serwadda D, Kigozi G, Nalugoda F, Reynolds SJ, Wawer MJ, Singer ME. Indices to measure risk of HIV acquisition in Rakai, Uganda. PLoS One. 2014 Apr 4;9(4):e92015. doi: 10.1371/journal.pone.0092015. PMID: 24704778; PMCID: PMC3976261.
  6. Longosz AF, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O. Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr. 2014;65(4):390-6.
  7. Lusiba JK, Nakiyingi L, Kirenga BJ, Kiragga A, Lukande R, Nsereko M, Ssengooba W, Katamba A, Worodria W, Joloba ML, Mayanja-Kizza H. Evaluation of Cepheid's Xpert MTB/RIF Test on Pleural Fluid in the Diagnosis of Pleural Tuberculosis in a High Prevalence HIV/TB Setting. PLoS One. 2014;9(7):e102702.
  8. Ma N, Zalwango S, Malone LL, Nsereko M, Wampande EM, Thiel BA, Okware B, Igo RP Jr, Joloba ML, Mupere E, Mayanja-Kizza H, Boom WH, Stein CM, Tuberculosis Research U. Clinical and epidemiological characteristics of individuals resistant to M. tuberculosis infection in a longitudinal TB household contact study in Kampala, Uganda. BMC Infect Dis. 2014;14:352.
  9. Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, Belisle JT. A metabolic biosignature of early response to anti-tuberculosis treatment. BMC Infect Dis. 2014 Jan 31;14:53. doi: 10.1186/1471-2334-14-53. PMID: 24484441; PMCID: PMC3918231.
  10. McGrath JW, Winchester MS, Kaawa-Mafigiri D, Walakira E, Namutiibwa F, Birungi J, Ssendegye G, Nalwoga A, Kyarikunda E, Kisakye S, Ayebazibwe N, Rwabukwali CB. Challenging the paradigm: anthropological perspectives on HIV as a chronic disease. Med Anthropol. 2014;33(4):303-17. doi: 10.1080/01459740.2014.892483. PMID: 24661100; PMCID: PMC4390365.
  11. Mupere E, Malone L, Zalwango S, Okwera A, Nsereko M, Tisch DJ, Parraga IM, Stein CM, Mugerwa R, Boom WH, Mayanja HK, Whalen CC; Tuberculosis Research Unit at Case Western Reserve University. Wasting among Uganda men with pulmonary tuberculosis is associated with linear regain in lean tissue mass during and after treatment in contrast to women with wasting who regain fat tissue mass: prospective cohort study. BMC Infect Dis. 2014 Jan 13;14:24. doi: 10.1186/1471-2334-14-24. PMID: 24410970; PMCID: PMC3922730.
  12. Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. Aptamer based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb). 2014 May;94(3):187-96. doi: 10.1016/j.tube.2014.01.006. Epub 2014 Feb 7. PMID: 24629635; PMCID: PMC4028389.
  13. Nakku-Joloba E, Kambugu F, Wasubire J, Kimeze J, Salata R, Albert JM, Rimm A, Whalen C. Sero-prevalence of herpes simplex type 2 virus (HSV-2) and HIV infection in Kampala, Uganda. Afr Health Sci. 2014 Dec;14(4):782-9. doi: 10.4314/ahs.v14i4.2. PMID: 25834483; PMCID: PMC4370054.
  14. Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, Ameda F, Bugeza S, McComsey G, Freers J, Nakanjako D. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PLoS One. 2014 Feb 28;9(2):e89537. doi: 10.1371/journal.pone.0089537. PMID: 24586854; PMCID: PMC3938501.
  15. Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, Mayanja-Kizza H, Boom WH, Thiel BA, Crampin AC, Hanekom W, Ota MO, Dockrell H, Walzl G, Kaufmann SH, Ottenhoff TH, consortium GBfT. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect. 2014;20(4):O230-8.
  16. Toossi Z, Liu S, Wu M, Mayanja-Kizza H, Hirsch CS. Short Communication: Circulating Plasma HIV-1 Viral Protein R in Dual HIV-1/Tuberculosis Infection. AIDS Res Hum Retroviruses. 2014;30(7):644-7.
  17. Wekesa C, Kirenga BJ, Joloba ML, Bwanga F, Katamba A, Kamya MR. Chest X-ray vs. Xpert(R) MTB/RIF assay for the diagnosis of sputum smear-negative tuberculosis in Uganda. Int J Tuberc Lung Dis. 2014;18(2):216-9.

  1. Bark CM, Gitta P, Ogwang S, Nsereko M, Thiel BA, Boom WH, Eisenach KD, Joloba ML, Johnson JL. Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2013;17(11):1448-51.

  2. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One. 2013 Apr 18;8(4):e61002. doi: 10.1371/journal.pone.0061002

  3. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, Vernon A, Villarino ME, Burman WJ. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc. 2013 Feb;10(1):18-25. doi: 10.1513/AnnalsATS.201207-038OC

  4. Jaganath D, Zalwango S, Okware B, Nsereko M, Kisingo H, Malone L, Lancioni C, Okwera A, Joloba M, Mayanja-Kizza H, Boom WH, Stein C, Mupere E. Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis. 2013 Dec;57(12):1685-92. doi: 10.1093/cid/cit645

  5. Kyeyune F, Nankya I, Metha S, Akao J, Ndashimye E, Tebit DM, Rodriguez B, Kityo C, Salata RA, Mugyenyi P, Arts E, Group JDRW. Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS. 2013;27(12):1899-909.

  6. Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A, Eisenach K, Cave MD, Whalen CC, Johnson JL, Boom WH, Joloba M. Relapse more common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda. Int J Tuberc Lung Dis. 2013 Mar;17(3):361-7. doi: 10.5588/ijtld.11.0692

  7. Nyendak MR, Park B, Null MD, Baseke J, Swarbrick G, Mayanja-Kizza H, Nsereko M, Johnson DF, Gitta P, Okwera A, Goldberg S, Bozeman L, Johnson JL, Boom WH, Lewinsohn DA, Lewinsohn DM. Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One. 2013 Dec 4;8(12):e81564. doi: 10.1371/journal.pone.0081564

  8. Obuku EA, Parikh SM, Nankabirwa V, Kakande NI, Mafigiri DK, Mayanja-Kizza H, Kityo CM, Mugyenyi PN, Salata RA. Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda. PLoS One. 2013;8(2):e57028. doi: 10.1371/journal.pone.0057028

  9. Okwera A, Bwanga F, Najjingo I, Mulumba Y, Mafigiri DK, Whalen CC, Joloba ML. Aetiology of pulmonary symptoms in HIV-infected smear negative recurrent PTB suspects in Kampala, Uganda: a cross-sectional study. PLoS One. 2013 Dec 3;8(12):e82257. doi: 10.1371/journal.pone.0082257

  10. Parikh SM, Obuku EA, Walker SA, Semeere AS, Auerbach BJ, Hakim JG, Mayanja-Kizza H, Mugyenyi PN, Salata RA, Kityo CM. Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial. PLoS One. 2013 Oct 2;8(10):e76158. doi: 10.1371/journal.pone.0076158

  11. Stein CM, Hall NB, Malone LL, Mupere E. The household contact study design for genetic epidemiological studies of infectious diseases. Front Genet. 2013 Apr 30;4:61. doi: 10.3389/fgene.2013.00061. PMID: 23641253; PMCID: PMC3639375.

  12. Tao L, Zalwango S, Chervenak K, Thiel B, Malone LL, Qiu F, Mayanja-Kizza H, Boom WH, Stein CM. Genetic and Shared Environmental Influences on Interferon-gamma Production in Response to Mycobacterium tuberculosis Antigens in a Ugandan Population. Am J Trop Med Hyg. 2013.

  13. Toossi Z, Funderburg NT, Sirdeshmuk S, Whalen CC, Nanteza MW, Johnson DF, Mayanja-Kizza H, Hirsch CS. Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects. J Infect Dis. 2013 Jun 15;207(12):1841-9. doi: 10.1093/infdis/jit092. PMID: 23479321; PMCID: PMC3654743.

  14. Wampande EM, Mupere E, Debanne SM, Asiimwe BB, Nsereko M, Mayanja H, Eisenach K, Kaplan G, Boom HW, Sebastien G, Joloba ML. Long-term dominance of Mycobacterium tuberculosis Uganda family in peri-urban Kampala-Uganda is not associated with cavitary disease. BMC Infect Dis. 2013;13(1):484.

  15. Winchester MS, McGrath JW, Kaawa-Mafigiri D, Namutiibwa F, Ssendegye G, Nalwoga A, Kyarikunda E, Birungi J, Kisakye S, Ayebazibwe N, Walakira E, Rwabukwali CB. Early HIV disclosure and nondisclosure among men and women on antiretroviral treatment in Uganda. AIDS Care. 2013;25(10):1253-8. doi: 10.1080/09540121.2013.764386. PMID: 23356654; PMCID: PMC3657329.

  1. Baker AR, Qiu F, Randhawa AK, Horne DJ, Adams MD, Shey M, Barnholtz-Sloan J, Mayanja-Kizza H, Kaplan G, Hanekom WA, Boom WH, Hawn TR, Stein CM; Tuberculosis Research Unit and South African Tuberculosis Vaccine Initiative Team. Genetic variation in TLR genes in Ugandan and South African populations and comparison with HapMap data. PLoS One. 2012;7(10):e47597. doi: 10.1371/journal.pone.0047597. PMID: 23112821; PMCID: PMC3480404.

  2. Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy. J Clin Microbiol. 2012;50(2):538.

  3. Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE. Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. Int J Tuberc Lung Dis. 2012;16(4):473-9.

  4. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206(7):1030-40.

  5. Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis (Edinb). 2012 May;92(3):243-7. doi: 10.1016/j.tube.2012.02.004. PMID: 22406155; PMCID: PMC4408545.

  6. Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis. 2012;206(12):1809-15.

  7. Johnson JL, Thiel BA. Time until relapse in tuberculosis treatment trials: implication for phase 3 trial design. Am J Respir Crit Care Med. 2012;186(5):464.

  8. Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment. Int J Tuberc Lung Dis. 2012;16(4):480-5.

  9. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF, Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. CD8+ T cells provide an immunologic signature of tuberculosis in young children. Am J Respir Crit Care Med. 2012;185(2):206-12.

  10. Mafigiri DK, McGrath JW, Whalen CC. Task shifting for tuberculosis control: a qualitative study of community-based directly observed therapy in urban Uganda. Glob Public Health. 2012;7(3):270-84.

  11. Mahapatra S, Woolhiser LK, Lenaerts AJ, Johnson JL, Eisenach KD, Joloba ML, Boom WH, Belisle JT. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob Agents Chemother. 2012 Jan;56(1):28-35. doi: 10.1128/AAC.05486-11. PMID: 22037847; PMCID: PMC3256082.

  12. Mahon RN, Sande OJ, Rojas RE, Levine AD, Harding CV, Boom WH. Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation. Cell Immunol. 2012;275(1-2):98-105.

  13. Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, Baseke J, Dobbs D, Stein CM, Mayanja H, Joloba M, Whalen CC, Boom WH. Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. Am J Trop Med Hyg. 2012 Apr;86(4):690-7. doi: 10.4269/ajtmh.2012.11-0553. PMID: 22492155; PMCID: PMC3403758.

  14. McGrath JW, Kaawa-Mafigiri D, Bridges S, Kakande N. 'Slipping through the cracks': policy implications of delays in HIV treatment seeking. Glob Public Health. 2012;7(10):1095-108.

  15. Muchwa C, Akol J, Etwom A, Morgan K, Orikiriza P, Mumbowa F, Odong PR, Kateete DP, Eisenach KD, Joloba ML. Evaluation of Capilia TB assay for rapid identification of Mycobacterium tuberculosis complex in BACTEC MGIT 960 and BACTEC 9120 blood cultures. BMC Res Notes. 2012 Jan 19;5:44. doi: 10.1186/1756-0500-5-44. PMID: 22260090; PMCID: PMC3282630.

  16. Mupere E, Malone L, Zalwango S, Chiunda A, Okwera A, Mugerwa R, Whalen C. Body composition among HIV-seropositive and HIV-seronegative adult patients with pulmonary tuberculosis in Uganda. Ann Epidemiol. 2012;20(3):210-6.

  17. Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. Curr Opin Oncol. 2012;22(5):437-42.

  18. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2012 May 20;7(5):e37777. doi: 10.1371/journal.pone.0037777. PMID: 22647776; PMCID: PMC3367177.

  19. Namagembe I, Jackson LW, Zullo MD, Frank SH, Byamugisha JK, Sethi AK. Consumption of alcoholic beverages among pregnant urban Ugandan women. Matern Child Health J. 2012;16(4):502-508.

  20. Seicean A, Chiunda A, Seicean S, Mupere E, Babikako H, Helmus D, Scott F, Neuhauser D. Health services research in sub-Saharan Africa: thirty recommended examples. J Health Serv Res Policy. 2012;17(3):185-7.

  21. Stout JE, Kosinski AS, Hamilton CD, Goodman PC, Mosher A, Menzies D, Schluger N, Khan A, Johnson JL; Tuberculosis Trials Consortium. Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse. Acad Radiol. 2012 Feb;19(2):157-62.

  22. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2012 Oct;56(10):5912-200. doi: 10.1128/AAC.00561-12. PMID: 22917775; PMCID: PMC3457177.

  23. Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol. 2012;50(12):4370-6.

  1. Okwera A. Tuberculin reactions in apparently healthy HIV-seropositive and HIV-seronegative women - Uganda. MMWR. 1990;39:2.

  1. Babikako HM, Neuhauser D, Katamba A, Mupere E. Feasibility, reliability and validity of health-related quality of life questionnaire among adult pulmonary tuberculosis patients in urban Uganda: cross-sectional study. Health Qual Life Outcomes. 2010 Sep 2;8:93. doi: 10.1186/1477-7525-8-93. PMID: 20813062; PMCID: PMC2944342.

  2. Bark CM, Morrison CS, Salata RA, Byamugisha JK, Katalemwa NH, Mugerwa RD, Mukasa JB, Musoke RN, Nankya-Mutyoba J, Rwambuya S, Walker CJ, Johnson JL. Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda. Int J Tuberc Lung Dis. 2010;14(12):1647-9.

  3. Chamie G, Charlebois ED, Srikantiah P, Walusimbi-Nanteza M, Mugerwa RD, Mayanja H, Okwera A, Whalen CC, Havlir DV. Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count. Clin Infect Dis. 2010;51(3):359-62.

  4. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010;14(10):1295-302.

  5. Dickman KR, Nabyonga L, Kateete DP, Katabazi FA, Asiimwe BB, Mayanja HK, Okwera A, Whalen C, Joloba ML. Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis. 2010 Dec 10;10:349. doi: 10.1186/1471-2334-10-349. PMID: 21143966; PMCID: PMC3004912.

  6. Joloba ML, Kidenya BR, Kateete DP, Katabazi FA, Muwanguzi JK, Asiimwe BB, Alarakol SP, Nakavuma JL, Bajaksouzian S, Windau A, Jacobs MR. Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes. Int J Antimicrob Agents. 2010 Aug;36(2):124-8. doi: 10.1016/j.ijantimicag.2010.03.024. PMID: 20472405; PMCID: PMC2902549.

  7. Kateete DP, Okee M, Katabazi FA, Okeng A, Asiimwe J, Boom HW, Eisenach KD, Joloba ML. Rhomboid homologs in mycobacteria: insights from phylogeny and genomic analysis. BMC Microbiol. 2010 Oct 29;10:272. doi: 10.1186/1471-2180-10-272. PMID: 21029479; PMCID: PMC2989971.

  8. Koroukian SM, Xu F, Bakaki PM, Diaz-Insua M, Towe TP, Owusu C. Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J Gerontol A Biol Sci Med Sci. 2010;65(3):322-9.

  9. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Goletti D, Toossi Z, Lange C. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J. 2010;35(3):619-26.

  10. Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol. 2010;48(1):46-51.

  11. Liu C, Babigumira J, Chiunda A, Katamba A, Litvak I, Miller L, Namagembe I, Sekandi J, Seicean A, Seicean S, Neuhauser D. Finding the best examples of healthcare quality improvement in Sub-Saharan Africa. Qual Saf Health Care. 2010;19(5):416-9.

  12. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH. Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. PLoS One. 2010;5(2):e9138.

  13. Mugwanya KK, Baeten JM, Nakku-Joloba E, Katabira E, Celum C, Tisch D, Whalen C. Knowledge and attitudes about male circumcision for HIV-1 prevention among heterosexual HIV-1 serodiscordant partnerships in Kampala, Uganda. AIDS Behav. 2010 Oct;14(5):1190-7. doi: 10.1007/s10461-010-9696-x. PMID: 20387112; PMCID: PMC4562410.

  14. Mupere E, Zalwango S, Chiunda A, Okwera A, Mugerwa R, Whalen C. Body composition among HIV-seropositive and HIV-seronegative adult patients with pulmonary tuberculosis in Uganda. Ann Epidemiol. 2010;20(3):210-6.

  15. Nagaiah G, Stotler C, Orem J, Mwanda WO, Remick SC. Ocular surface squamous neoplasia in patients with HIV infection in sub-Saharan Africa. Curr Opin Oncol. 2010;22(5):437-42.

  16. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2012 May 20;7(5):e37777. doi: 10.1371/journal.pone.0037777. PMID: 22647776; PMCID: PMC3367177.

  17. Namagembe I, Jackson LW, Zullo MD, Frank SH, Byamugisha JK, Sethi AK. Consumption of alcoholic beverages among pregnant urban Ugandan women. Matern Child Health J. 2012;16(4):502-508.

  18. Seicean A, Chiunda A, Seicean S, Mupere E, Babikako H, Helmus D, Scott F, Neuhauser D. Health services research in sub-Saharan Africa: thirty recommended examples. J Health Serv Res Policy. 2012;17(3):185-7.

  19. Stout JE, Kosinski AS, Hamilton CD, Goodman PC, Mosher A, Menzies D, Schluger N, Khan A, Johnson JL; Tuberculosis Trials Consortium. Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse. Acad Radiol. 2012 Feb;19(2):157-62.

  20. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2012 Oct;56(10):5912-200. doi: 10.1128/AAC.00561-12. PMID: 22917775; PMCID: PMC3457177.

  21. Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol. 2012;50(12):4370-6.

  1. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, Katzenstein D, Siddiqui A, Herrera C, Fischetti L, Shattock RJ, Arts EJ. CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J Virol. 2009;83(11):5592-605.

  2. Babigumira JB, Sethi AK, Smyth KA, Singer ME. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. PharmacoEconomics. 2009;27(11):963-73.

  3. Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM, Sethi AK. Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic). 2009;8(2):139-47.

  4. Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care. 2009;21(3):271-9.

  5. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, Boom WH, Dockrell HM, Franken KL, Friggen AH, Hill PC, Klein MR, Lalor MK, Mayanja H, Schoolnik G, Stanley K, Weldingh K, Kaufmann SH, Walzl G, Ottenhoff TH; GCGH Biomarkers for TB Consortium. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol. 2009 Aug;16(8):1203-12. doi: 10.1128/CVI.00111-09. PMID: 19553548; PMCID: PMC2725533.

  1. Asiimwe S, Whalen CC, Tisch DJ, Tumwesigye E, Sethi AK. Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda. International journal of STD & AIDS. 2008;19(9):605-10.

  2. Gao Y, Lobritz MA, Roth J, Abreha M, Nelson KN, Nankya I, Moore-Dudley DM, Abraha A, Gerson SL, Arts EJ. Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. Journal of virology. 2008;82(6):2938-51.

  3. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, Toossi Z. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC infectious diseases. 2008;8:11.

  4. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22(4):481-7.

  5. Lewinsohn DA, Zalwango S, Stein CM, Mayanja-Kizza H, Okwera A, Boom WH, Mugerwa RD, Whalen CC. Whole blood interferon-gamma responses to mycobacterium tuberculosis antigens in young household contacts of persons with tuberculosis in Uganda. PloS one. 2008;3(10):e3407.

  6. Pearson R, Kim YK, Hokello J, Lassen K, Friedman J, Tyagi M, Karn J. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. Journal of virology. 2008;82(24):12291-303.

  7. Salyer JL, Walusimbi ML, Fitzpatrick JJ. Knowledge and attitudes of Ugandan midwives regarding HIV. The Journal of the Association of Nurses in AIDS Care: JANAC. 2008;19(2):105-13.

  8. Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, Kayanja HK, Mugerwa RD, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis. J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):458-60. doi: 10.1097/QAI.0b013e31817e9fb4. PMID: 19011423; PMCID: PMC4752197.

  9. Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, Thompson CL, Cartier KC, Elston RC, Iyengar SK, Boom WH, Whalen CC. Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One. 2008;3(12):e4094. doi: 10.1371/journal.pone.0004094. PMID: 19116662; PMCID: PMC2605555.

  10. Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, Nakubulwa S, Worodria W, Levin J, Joloba M, Okwera A, Eisenach KD, McNerney R, Elliott AM, Smith PG, Mugerwa RD, Ellner JJ, Jones-López EC. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis. 2008 Nov 1;47(9):1126-34. doi: 10.1086/592252. PMID: 18808360; PMCID: PMC2883442.

  11. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugyenyi P, et al. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS research and human retroviruses. 2008;24(2):235-50.

  1. Best M, Katamba A, Neuhauser D. Making the right decision: Benjamin Franklin's son dies of smallpox in 1736. Quality & safety in health care. 2007;16(6):478-80.

  2. Blossom DB, Cordeiro SM, Bajaksouzian S, Joloba ML, Kityo C, Whalen CC, Salata RA, Jacobs MR. Characterisation of penicillin intermediate serotypes of Streptococcus pneumoniae carried by human immunodeficiency virus-infected adults and healthy children in Uganda. Microb Drug Resist. 2007;13(1):21-8.

  3. Lalonde MS, Troyer RM, Syed AR, Bulime S, Demers K, Bajunirwe F, Arts EJ. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. Journal of clinical microbiology. 2007;45(8):2604-15.

  4. McGrath JW, Celentano DD, Chard SE, Fullem A, Kamya M, Gangakhedar RR, Khamboonruang C, Joglekar N, Malhotra-Kohli R, Kiwanuka A, Sirirojn B. A group-based intervention to increase condom use among HIV serodiscordant couples in India, Thailand, and Uganda. AIDS care. 2007;19(3):418-24.

  5. Nakanjako D, Kamya M, Daniel K, Mayanja-Kizza H, Freers J, Whalen C, Katabira E. Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS and behavior. 2007;11(5):753-8.

  6. Meya DB, Katabira E, Otim M, Ronald A, Colebunders R, Njama D, Mayanja-Kizza H, Whalen CC, Sande M. Functional adrenal insufficiency among critically ill patients with human immunodeficiency virus in a resource-limited setting. African health sciences. 2007;7(2):101-7.

  7. Srikantiah P, Lin R, Walusimbi M, Okwera A, Luzze H, Whalen CC, Boom WH, Havlir DV, Charlebois ED. Elevated HIV seroprevalence and risk behavior among Ugandan TB suspects: implications for HIV testing and prevention. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2007;11(2):168-74.

  8. Srikantiah P, Walusimbi MN, Kayanja HK, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS. 2007;21(14):1972-4.

  9. Stein CM, Zalwango S, Chiunda AB, Millard C, Leontiev DV, Horvath AL, Cartier KC, Chervenak K, Boom WH, Elston RC, Mugerwa RD, Whalen CC, Iyengar SK. Linkage and association analysis of candidate genes for TB and TNFalpha cytokine expression: evidence for association with IFNGR1, IL-10, and TNF receptor 1 genes. Human genetics. 2007;121(6):663-73.

  10. Tebit DM, Nankya I, Arts EJ, Gao Y. HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS reviews. 2007;9(2):75-87.

  11. Toossi Z, Mayanja-Kizza H, Lawn SD, Hirsch CS, Lupo LD, Butera ST. Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS research and human retroviruses. 2007;23(1):93-100.

  12. Traore H, Ogwang S, Mallard K, Joloba ML, Mumbowa F, Narayan K, Kayes S, Jones-Lopez EC, Smith PG, Ellner JJ, Mugerwa RD, Eisenach KD, McNerney R. Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Annals of clinical microbiology and antimicrobials. 2007;6:1.

  1. Bagenda D, Nassali A, Kalyesubula I, Sherman B, Drotar D, Boivin MJ, Olness K. Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviral-naive Ugandan children. Pediatrics. 2006;117(3):729-40.

  2. Blossom DB, Namayanja-Kaye G, Nankya-Mutyoba J, Mukasa JB, Bakka H, Rwambuya S, Windau A, Bajaksouzian S, Walker CJ, Joloba ML, Kityo C, Mugyenyi P, Whalen CC, Jacobs MR, Salata RA. Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. International journal of infectious diseases: IJID : official publication of the International Society for Infectious Diseases. 2006;10(6):458-64.

  3. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. American journal of respiratory and critical care medicine. 2006;174(3):331-8.

  4. Ddungu H, Johnson JL, Smieja M, Mayanja-Kizza H. Digital clubbing in tuberculosis--relationship to HIV infection, extent of disease and hypoalbuminemia. BMC infectious diseases. 2006;6:45.

  5. Jones-Lopez EC, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC. Delayed-type hypersensitivity skin test reactivity and survival in HIV-infected patients in Uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries? The American journal of tropical medicine and hygiene. 2006;74(1):154-61.

  6. Lim HJ, Okwera A, Mayanja-Kizza H, Ellner JJ, Mugerwa RD, Whalen CC. Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. HIV clinical trials. 2006;7(4):172-83.

  7. Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, Mugerwa RD, Boom H, Eisenach KD, Joloba ML. Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2006;10(11):1262-7.

  8. Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2006;10(1):39-44.

  9. Orem J, Otieno MW, Remick SC. Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Current opinion in oncology. 2006;18(5):479-86.

  10. Whalen CC, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E, Okwera A, Hirsch C, Peters P, Boom WH, Mugerwa RD. Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. The American journal of tropical medicine and hygiene. 2006;75(1):55-61.

  1. Hirsch CS, Johnson JL, Okwera A, Kanost RA, Wu M, Peters P, Muhumuza M, Mayanja-Kizza H, Mugerwa RD, Mugyenyi P, Ellner JJ, Toossi Z. Mechanisms of apoptosis of T-cells in human tuberculosis. Journal of clinical immunology. 2005;25(4):353-64.

  2. Iriso R, Mudido PM, Karamagi C, Whalen C. The diagnosis of childhood tuberculosis in an HIV-endemic setting and the use of induced sputum. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2005;9(7):716-26.

  3. Jones-Lopez EC, Ellner JJ. Tuberculosis infection among HCWs. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2005;9(6):591.

  4. Jones-Lopez EC, Ellner JJ, Whalen CC. Subclinical tuberculosis: a new entity? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2005;41(7):1069-70; author reply 70-1.

  5. Katamba A, Neuhauser DB, Smyth KA, Adatu F, Katabira E, Whalen CC. Patients perceived stigma associated with community-based directly observed therapy of tuberculosis in Uganda. East African medical journal. 2005;82(7):337-42.

  6. Kayanja HK, Debanne S, King C, Whalen CC. Tuberculosis infection among health care workers in Kampala, Uganda. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2005;9(6):686-8.

  7. Kizza HM, Rodriguez B, Quinones-Mateu M, Mirza M, Aung H, Yen-Lieberman B, Starkey C, Horter L, Peters P, Baseke J, Johnson JL, Toossi Z. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clinical and diagnostic laboratory immunology. 2005;12(11):1298-304.

  8. Mayanja-Kizza H, Jones-Lopez E, Okwera A, Wallis RS, Ellner JJ, Mugerwa RD, Whalen CC. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. The Journal of infectious diseases. 2005;191(6):856-65.

  9. Mwanda WO, Fu P, Collea R, Whalen C, Remick SC. Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Annals of tropical medicine and parasitology. 2005;99(1):81-91.

  10. Mwanda WO, Orem J, Remick SC, Rochford R, Whalen C, Wilson ML. Clinical characteristics of Burkitt's lymphoma from three regions in Kenya. East African medical journal. 2005;82(9 Suppl):S135-43.

  11. Mwanda WO, Whalen C, Remick SC. Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East African medical journal. 2005;82(9 Suppl):S133-4.

  12. Namayanja GK, Nankya JM, Byamugisha JK, Ssali FN, Kityo CM, Rwambuya SD, Mugerwa RD, Mmiro FA, Morrison CS, Salata RA. Stevens - Johnson syndrome due to nevirapine. African health sciences. 2005;5(4):338-40.

  13. Orem J, Fu P, Ness A, Mwanda WO, Remick SC. Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease. East African medical journal. 2005;82(9 Suppl):S144-9.

  14. Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ayers L, Ghannoum M, Fu P, Feigal EG, Black J, Whalen C, Lederman M, Remick SC. Capacity building for the clinical investigation of AIDS malignancy in East Africa. Cancer detection and prevention. 2005;29(2):133-45.

  15. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC. Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East African medical journal. 2005;82(9 Suppl):S155-60.

  16. Rojas RE, Chervenak KA, Thomas J, Morrow J, Nshuti L, Zalwango S, Mugerwa RD, Thiel BA, Whalen CC, Boom WH. Vdelta2+ gammadelta T cell function in Mycobacterium tuberculosis- and HIV-1-positive patients in the United States and Uganda: application of a whole-blood assay. The Journal of infectious diseases. 2005;192(10):1806-14.

  17. Stein CM, Nshuti L, Chiunda AB, Boom WH, Elston RC, Mugerwa RD, Iyengar SK, Whalen CC. Evidence for a major gene influence on tumor necrosis factor-alpha expression in tuberculosis: path and segregation analysis. Human heredity. 2005;60(2):109-18.

  18. Toossi Z, Mayanja-Kizza H, Baseke J, Peters P, Wu M, Abraha A, Aung H, Okwera A, Hirsch C, Arts E. Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis. Clinical and experimental immunology. 2005;142(2):327-32.

  1. Bajunirwe F, Massaquoi I, Asiimwe S, Kamya MR, Arts EJ, Whalen CC. Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda. African health sciences. 2004;4(3):146-54.

  2. Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Ducar C, Ellner JJ, Whitworth JA, Mugerwa R, Johnson JL, Okwera A. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. The Journal of infectious diseases. 2004;190(5):869-78.

  3. Guwatudde D, Debanne SM, Diaz M, King C, Whalen CC. A re-examination of the potential impact of preventive therapy on the public health problem of tuberculosis in contemporary sub-Saharan Africa. Preventive medicine. 2004;39(5):1036-46.

  4. Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Mwinga A, Chintu C, Ngwira B, Onyebujoh P, Zumla A. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2004;8(11):1348-54.

  5. Johnson JL, Okwera A, Horter L, Whalen CC, Mugerwa RD. Rifampicin-containing regimens for the treatment of latent tuberculosis infection also prevented diarrheal illnesses in HIV-infected Ugandan adults. AIDS. 2004;18(4):706-8.

  6. Joloba ML, Clemmer KM, Sledjeski DD, Rather PN. Activation of the gab operon in an RpoS-dependent manner by mutations that truncate the inner core of lipopolysaccharide in Escherichia coli. Journal of bacteriology. 2004;186(24):8542-6.

  7. Marozsan AJ, Fraundorf E, Abraha A, Baird H, Moore D, Troyer R, Nankja I, Arts EJ. Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. Journal of virology. 2004;78(20):11130-41.

  8. Musil CM, Mutabaazi J, Walusimbi M, Okonsky JG, Biribonwa Y, Eagan S, Dimarco MA, Mbaballi S, Fitzpatrick JJ. Considerations for preparing collaborative international research: a Ugandan experience. Applied nursing research: ANR. 2004;17(3):195-200.

  9. Mwanda OW, Whalen C, Scot CR, Lederman M, Orem J, Banura C. Anatomical site predilections of non-Hodgkin's lymphoma in human immunodeficiency virus infection: a report on 54 cases. East African medical journal. 2004(8 Suppl):S90-6.

  10. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Current opinion in oncology. 2004;16(5):468-76.

  11. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS research and human retroviruses. 2004;20(4):355-64.

  12. Toossi Z, Mayanja-Kizza H, Kanost A, Edmonds K, McHugh M, Hirsch C. Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by Mycobacterium tuberculosis and during human tuberculosis. Scandinavian journal of immunology. 2004;60(3):299-306.

  13. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, Ducar C, Millard M, Mayanja-Kizza H, Whalen C, Okwera A. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18(2):257-64.

  14. Wallis RS, Song HY, Whalen C, Okwera A. TB chemotherapy: antagonism between immunity and sterilization. American journal of respiratory and critical care medicine. 2004;169(6):771-2.

  15. Walusimbi M, Okonsky JG. Knowledge and attitude of nurses caring for patients with HIV/AIDS in Uganda. Applied nursing research: ANR. 2004;17(2):92-9.

  1. Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. The Journal of infectious diseases. 2003;187(6):887-95.

  2. Guwatudde D, Nakakeeto M, Jones-Lopez EC, Maganda A, Chiunda A, Mugerwa RD, Ellner JJ, Bukenya G, Whalen CC. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. American journal of epidemiology. 2003;158(9):887-98.

  3. Guwatudde D, Zalwango S, Kamya MR, Debanne SM, Diaz MI, Okwera A, Mugerwa RD, King C, Whalen CC. Burden of tuberculosis in Kampala, Uganda. Bulletin of the World Health Organization. 2003;81(11):799-805.

  4. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. American journal of respiratory and critical care medicine. 2003;168(2):185-91.

  5. Joloba ML, Rather PN. Mutations in deoB and deoC alter an extracellular signaling pathway required for activation of the gab operon in Escherichia coli. FEMS microbiology letters. 2003;228(1):151-7.

  6. Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. African health sciences. 2003;3(2):61-7.

  7. Sherman SG, Celentano DA, McGrath JW, Chard SE, Gangakhedkar RR, Joglekar N, Malhotra-Kohli R, Kamya M, Fullem A. The reliability and validity of the Modified Condom Outcome Expectancy Scale (MCOES) among an international sample of HIV-negative partners of people living with HIV/AIDS. AIDS care. 2003;15(3):359-66.

  8. Stein CM, Guwatudde D, Nakakeeto M, Peters P, Elston RC, Tiwari HK, Mugerwa R, Whalen CC. Heritability analysis of cytokines as intermediate phenotypes of tuberculosis. The Journal of infectious diseases. 2003;187(11):1679-85.

Our Vision

The Uganda Case Research Collaboration’s vision is “Conducting high quality research towards improved health”

Our Mission

To conduct relevant and integrated research, capacity building and improve the quality of life of patients through training and care

Our Values

  • Respect
  • Integrity
  • Innovation
  • Compassion

Latest News

All News